Cited by 19Heart Failure Treatment and ManagementGrowth Hormone and Insulin-like Growth FactorsHormonal and reproductive studies

GH Therapy in Chronic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Open access
Theodorakis, Nikolaos, Feretzakis, Georgios, Kreouzi, Magdalini, Anagnostou, Dimitrios, Hitas, Christos, Verykios, Vassilios S, Nikolaou, Maria·2025·The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Guideline-directed medical therapy of heart failure (HF) primarily targets neurohormonal activation. However, GH has emerged as a potential treatment for the multiple hormonal deficiency syndrome, which is associated with worse outcomes in HF. Objective: This study evaluates the efficacy and safety of GH therapy in HF. Data Sources: A systematic search was conducted in PubMed, Cochrane Library, and ClinicalTrials.gov, according to PRISMA guidelines Study Selection: Randomized, placebo-controlled trials studying GH therapy in adult HF patients were included. Of the 1184 initially identified records, 17 studies (1.4%) met the inclusion criteria. Data extraction: Two independent authors conducted the search, with any disagreements resolved by a third author. Study quality was assessed using predefined criteria, including randomization, blinding, and the presence of a placebo group. Data Synthesis: A random-effects model was applied due to heterogeneity across studies. GH therapy significantly improved left ventricular ejection fraction (+3.34%; 95% CI, 1.09-5.59; P = .0037), peak oxygen consumption (+2.84 mL/kg/min; 95% CI, 1.32-4.36; P = .0002), and New York Heart Association class (−0.44; 95% CI, −0.08 to −0.81; P = .023). GH therapy also reduced the composite of death, worsening HF or ventricular tachycardia by 41% (RR = .59; 95% CI, 0.39-0.90; P = .013). Subgroup analyses indicated that patients with ischemic cardiomyopathy, baseline ejection fraction ≥30%, and longer treatment duration experienced greater benefits. Conclusion: GH therapy demonstrated improvements in cardiac function, exercise capacity, and HF symptoms, along with a statistically significant trend toward improvements in hard endpoints. Event-driven trials are needed to validate these findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgae814

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Theodorakis, N., Feretzakis, G., Kreouzi, M., Anagnostou, D., Hitas, C., Verykios, V. S., & Nikolaou, M.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • Hellenic Open University (GR)
  • Sismanoglio General Hospital (GR)
  • Simanogleio-Amalia Fleming General Hospital (GR)
Corresponding author
Feretzakis, Georgios
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2024-11-21
Volume
110
Issue
4
Pages
e1252-e1260
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4404554530
Cited by
19
References
30
Citations by year
2026: 3 · 2025: 13 · 2024: 3
FWCI
1.51
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Hellenic Academic Libraries Link
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
growth hormone therapy, chronic heart failure, left ventricular ejection fraction, peak oxygen uptake, NYHA functional class, mortality, ischemic cardiomyopathy, neurohormonal activation, exercise capacity
MeSH terms
Chronic Disease, Heart Failure, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review